Yahoo Web Search

Search results

1. • Genprex Announces the Passing of its Co-Founder and Chief Executive Officer, Rodney Varner

     WKRN Nashville· 3 days ago

     Ryan Confer Appointed Genprex President and CEO and to its Board of Directors AUSTIN, Texas, May 8, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage ...

2. • Biotech CEL-SCI gets FDA go-ahead to conduct investigational cancer immunotherapy study - Maryland...

     The Daily Record· 3 days ago

     The project will study the drug’s effectiveness in newly diagnosed advanced primary head and neck cancer patients with no lymph node involvement, determined via PET scan, and with low PD-L1 ...

3. • Nanoscope Therapeutics Announces Presentations in Upcoming ASGCT Annual Meeting and Retina World...

     FOX 5 San Diego· 4 days ago

     DALLAS, May 7, 2024 /PRNewswire/ -- Nanoscope Therapeutics Inc., a late-stage clinical biotechnology company developing gene therapies for retinal degenerative diseases, today announced that ...

4. • NeuroSense Announces New Positive Data Analysis from PARADIGM Clinical Trial Demonstrating...

     NBC 17 Raleigh· 4 days ago

     NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing novel treatments for severe neurodegenerative diseases, announces new analyses from its Phase 2b PARADIGM clinical ...

5. • Can-Fite BioPharma and Nutriband Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show...

     Digital Journal· 1 day ago

     ORLANDO, FL / ACCESSWIRE / May 10, 2024 / RedChip Companies will air interviews with Can-Fite BioPharma Ltd. (NYSE American:CANF) and Nutriband Inc. (NASDAQ:NTRB) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this

6. • RedHill Announces New Opaganib Chinese Patent Against Ebola Virus Valid Through 2035

     NBC 17 Raleigh· 5 days ago

     A host-directed and potentially broad acting twice-daily oral, small molecule, opaganib is in development for multiple indications, including COVID-19, acute respiratory distress syndrome, oncology ...

7. • Mirum Pharmaceuticals Inc (MIRM) Q1 2024 Earnings Call Transcript Highlights: Soaring Sales and ...

     GuruFocus.com via Yahoo Finance· 3 days ago

     This is based on historical data and is a starting point for the study. Q: Can you provide any updates on the potential for orphan drug status for Maralixibat ...

8. • How to find more information about a drug that your doctor prescribed

     The Conversation· 3 days ago

     You’ve just been given a prescription for a new drug from your doctor. Your doctor told you why she was prescribing the medication, gave you its name and some information about common side-effects ...

9. • Biodexa Looks To Prevent Or Delay The Worst Outcomes For Adolescents And Young Adults With...

     Digital Journal· 2 days ago

     Registrational phase 3 clinical trials of Biodexa's (NASDAQ:BDRX) candidate eRapa are expected to start first quarter next year. The candidate was developed with private funds and acquired by ...

10. • Small Business - Austin Daily Herald | Austin Daily Herald

      Austin Daily Herald· 2 days ago

      Company to host a webcast today at 8:30 a.m. Eastern Time NEW YORK, May 09, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated